コンテンツへスキップ
Merck

5.30537

JmjC Histone Demethylase Inhibitor, n-Octyl-IOX1

別名:

JmjC Histone Demethylase Inhibitor, n-Octyl-IOX1, KDM4 Inhibitor

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C18H23NO3
CAS番号:
分子量:
301.38
MDL number:
NACRES:
NA.77
UNSPSC Code:
12352200
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

gray-green

solubility

DMSO: 5 mg/mL

storage temp.

−20°C

Quality Level

関連するカテゴリー

Biochem/physiol Actions

Cell permeable: yes
Primary Target
KDM4
Reversible: yes

Disclaimer

Toxicity: Standard Handling (A)

General description

A cell-permeable, non-toxic, n-octyl ester form of 5-carboxy-8-hydroxyquinoline (IOX1, Cat. No. 420201) that acts as a superior inhibitor of Jumonji C domain histone lysine demethylase. Shown to be about 30 fold more potent than IOX1 (EC50 = 3.8 µM for KDM4A in HeLa cells vs. 100 µM for IOX1). Inhibits the H3K9 me3 demethylation activity of KDM4C (IC50 = 3.9 µM in ALPHA Screen assay). Exhibits greater stability to hydrolysis in the ALPHA Screen buffer.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Other Notes

Schiller, R., et al. 2014. ChemMedChem.9,566.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

関連コンテンツ

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)